{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:01:18Z","timestamp":1740135678867,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1245\/s10434-023-14420-4","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T15:02:41Z","timestamp":1697468561000},"page":"75-80","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Top Hepatobiliary Articles from 2022 to Inform Your Cancer Practice"],"prefix":"10.1245","volume":"31","author":[{"given":"Zachary J.","family":"Brown","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7994-9870","authenticated-orcid":false,"given":"Timothy M.","family":"Pawlik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,16]]},"reference":[{"issue":"4","key":"14420_CR1","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378\u201390.","journal-title":"N Engl J Med."},{"issue":"14","key":"14420_CR2","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381.","journal-title":"N Engl J Med."},{"issue":"4","key":"14420_CR3","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862\u201373.","journal-title":"J Hepatol."},{"issue":"3","key":"14420_CR4","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681\u201393.","journal-title":"J Hepatol."},{"issue":"6","key":"14420_CR5","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S2468-1253(22)00043-7","volume":"7","author":"DY Oh","year":"2022","unstructured":"Oh DY, Lee KH, Lee DW, et al. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. Lancet Gastroenterol Hepatol. 2022;7(6):522\u201332.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"14420_CR6","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1200\/JCO.2019.37.15_suppl.4079","volume":"37","author":"Y-J Bang","year":"2019","unstructured":"Bang Y-J, Ueno M, Malka D, et al. Pembrolizumab (pembro) for advanced biliary adenocarcinoma: results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies. J Clin Oncol. 2019;37:4079\u20134079.","journal-title":"J Clin Oncol."},{"issue":"22","key":"14420_CR7","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078\u201392.","journal-title":"N Engl J Med."},{"issue":"26","key":"14420_CR8","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517\u201326.","journal-title":"N Engl J Med."},{"issue":"4","key":"14420_CR9","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1001\/jamasurg.2022.7989","volume":"158","author":"ZJ Brown","year":"2023","unstructured":"Brown ZJ, Tsilimigras DI, Ruff SM, et al. Management of hepatocellular carcinoma: a review. JAMA Surg. 2023;158(4):410\u201320.","journal-title":"JAMA Surg."},{"issue":"12","key":"14420_CR10","doi-asserted-by":"publisher","first-page":"7231","DOI":"10.1245\/s10434-022-12242-4","volume":"29","author":"DI Tsilimigras","year":"2022","unstructured":"Tsilimigras DI, Aziz H, Pawlik TM. Critical analysis of the updated Barcelona clinic liver cancer (BCLC) group guidelines. Ann Surg Oncol. 2022;29(12):7231\u20134.","journal-title":"Ann Surg Oncol."},{"issue":"8","key":"14420_CR11","doi-asserted-by":"publisher","first-page":"EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1(8):EVIDoa2100070.","journal-title":"NEJM Evid."},{"issue":"27","key":"14420_CR12","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1200\/JCO.20.03555","volume":"39","author":"RK Kelley","year":"2021","unstructured":"Kelley RK, Sangro B, Harris W, et al. Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I\/II study. J Clin Oncol. 2021;39(27):2991\u20133001.","journal-title":"J Clin Oncol."},{"issue":"3","key":"14420_CR13","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1200\/JCO.21.00679","volume":"40","author":"JM Phelip","year":"2022","unstructured":"Phelip JM, Desrame J, Edeline J, et al. Modified FOLFIRINOX versus CISGEM chemotherapy for patients with advanced biliary tract cancer (PRODIGE 38 AMEBICA): a randomized phase II study. J Clin Oncol. 2022;40(3):262\u201371.","journal-title":"J Clin Oncol."},{"issue":"19","key":"14420_CR14","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817\u201325.","journal-title":"N Engl J Med."},{"issue":"8","key":"14420_CR15","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"D-Y Oh","year":"2022","unstructured":"Oh D-Y, He AR, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1(8):EVIDoa2200015.","journal-title":"NEJM Evid."},{"issue":"1","key":"14420_CR16","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/SLA.0000000000003852","volume":"275","author":"O Soubrane","year":"2022","unstructured":"Soubrane O, Eguchi S, Uemoto S, et al. Minimally invasive donor hepatectomy for adult living donor liver transplantation: an international, multi-institutional evaluation of safety, efficacy and early outcomes. Ann Surg. 2022;275(1):166\u201374.","journal-title":"Ann Surg."},{"issue":"4","key":"14420_CR17","first-page":"619","volume":"261","author":"G Wakabayashi","year":"2015","unstructured":"Wakabayashi G, Cherqui D, Geller DA, et al. Recommendations for laparoscopic liver resection: a report from the second international consensus conference held in Morioka. Ann Surg. 2015;261(4):619\u201329.","journal-title":"Ann Surg."},{"issue":"7","key":"14420_CR18","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1080\/13543784.2022.2079491","volume":"31","author":"ZJ Brown","year":"2022","unstructured":"Brown ZJ, Hewitt DB, Pawlik TM. Experimental drug treatments for hepatocellular carcinoma: clinical trial failures 2015 to 2021. Expert Opin Investig Drugs. 2022;31(7):693\u2013706.","journal-title":"Expert Opin Investig Drugs."},{"issue":"1","key":"14420_CR19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12885-019-5391-0","volume":"19","author":"PL Labib","year":"2019","unstructured":"Labib PL, Goodchild G, Pereira SP. Molecular pathogenesis of cholangiocarcinoma. BMC Cancer. 2019;19(1):185.","journal-title":"BMC Cancer."},{"issue":"6","key":"14420_CR20","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41419-018-0687-6","volume":"9","author":"ZJ Brown","year":"2018","unstructured":"Brown ZJ, Fu Q, Ma C, et al. Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4+ T cell apoptosis promoting HCC development. Cell Death Dis. 2018;9(6):620.","journal-title":"Cell Death Dis."},{"issue":"7593","key":"14420_CR21","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nature16969","volume":"531","author":"C Ma","year":"2016","unstructured":"Ma C, Kesarwala AH, Eggert T, et al. NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis. Nature. 2016;531(7593):253\u20137.","journal-title":"Nature."},{"issue":"3","key":"14420_CR22","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.jhep.2022.03.010","volume":"77","author":"S Wabitsch","year":"2022","unstructured":"Wabitsch S, McCallen JD, Kamenyeva O, et al. Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD. J Hepatol. 2022;77(3):748\u201360.","journal-title":"J Hepatol."},{"issue":"20","key":"14420_CR23","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u2013905.","journal-title":"N Engl J Med."},{"issue":"6391","key":"14420_CR24","doi-asserted-by":"publisher","first-page":"eaan5931","DOI":"10.1126\/science.aan5931","volume":"360","author":"C Ma","year":"2018","unstructured":"Ma C, Han M, Heinrich B, et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science. 2018;360(6391):eaan5931.","journal-title":"Science."},{"issue":"11","key":"14420_CR25","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJM199603143341104","volume":"334","author":"V Mazzaferro","year":"1996","unstructured":"Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693\u20139.","journal-title":"N Engl J Med."},{"issue":"5","key":"14420_CR26","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1111\/j.1600-6143.2011.03972.x","volume":"12","author":"MM Abecassis","year":"2012","unstructured":"Abecassis MM, Fisher RA, Olthoff KM, et al. Complications of living donor hepatic lobectomy\u2014a comprehensive report. Am J Transpl. 2012;12(5):1208\u201317.","journal-title":"Am J Transpl."},{"key":"14420_CR27","doi-asserted-by":"publisher","DOI":"10.1097\/LVT.0000000000000115","author":"IA Ziogas","year":"2023","unstructured":"Ziogas IA, Kakos CD, Moris DP, et al. Systematic review and meta-analysis of open versus laparoscopy-assisted versus pure laparoscopic versus robotic living donor hepatectomy. Liver Transpl. 2023. https:\/\/doi.org\/10.1097\/LVT.0000000000000115.","journal-title":"Liver Transpl."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-14420-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-023-14420-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-14420-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T21:38:00Z","timestamp":1701725880000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-023-14420-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,16]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["14420"],"URL":"https:\/\/doi.org\/10.1245\/s10434-023-14420-4","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"type":"print","value":"1068-9265"},{"type":"electronic","value":"1534-4681"}],"subject":[],"published":{"date-parts":[[2023,10,16]]},"assertion":[{"value":"22 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}